Consideration and discussion on ten hot issues of endocrine therapy for breast cancer.
- Author:
Zefei JIANG
1
,
2
;
Email: JIANGZF@HOTMAIL.COM.
;
Xiaodi WANG
Author Information
1. Center of Cancer, Academy of Military Medical Sciences, Beijing 100071, China
2. Email: jiangzf@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Breast Neoplasms;
Humans
- From:
Chinese Journal of Surgery
2015;53(12):895-900
- CountryChina
- Language:Chinese
-
Abstract:
Endocrine therapy is one of the main treatment for hormone receptor positive breast cancer. In recent years, some of the critical results of clinical studies have been published, triggering a heat discussion. Guidelines and expert consensus have made appropriate updates based on some results. However, the selection and duration of the endocrine therapy for premenopausal women, the judgment of the menstrual conditions, the application of ovarian function suppression and the choice of endocrine drug combining with ovarian function suppress, and monitoring the endometrial thickness and hormone levels during therapy, as well as the endocrine therapy for postmenopausal patients and metastatic cancer are still controversial. Based on the evidence from study and clinical experience, this article will focus and discuss the ten hot issues.
